PwPepwise

BPC-157

Healing & Recovery

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Preclinical injectable (systemic) protocols10 pg/kgOnce dailyIntraperitonealInjected into the abdominal cavity (research use).—
Preclinical oral protocols0.16 µg/mL—OralTaken by mouth.—
Topical/local administration10 µg/kg—TopicalApplied on the skin.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found in human gastric juice. Researchers have studied it for its potential to support healing across multiple tissues, including tendons, ligaments, muscle, bone, and the gastrointestinal tract. In preclinical models, BPC-157 appears to accelerate tendon and soft tissue repair9,12, protect the stomach lining from injury caused by stress, alcohol, NSAIDs, and antiplatelet drugs16,11, and promote the formation of new blood vessels to restore circulation in damaged tissue3,7. It may also support recovery from intestinal injury and colocutaneous fistulas10, and has been reported to reduce liver damage from radiation and drug toxicity13,18.

The evidence base is currently built primarily on animal and cell-based studies, with human clinical data actively emerging. A small retrospective case series suggested that intraarticular injection may provide pain relief in chronic knee conditions5, and a Phase 2 randomized controlled trial in acute hamstring injury is currently underway1. A Phase 1 safety and pharmacokinetics study in healthy volunteers has also been registered14. BPC-157 appears well-tolerated in preclinical models across a wide dose range9,17, and its human safety and efficacy profile is being established through ongoing clinical research.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from the sequence of human gastric juice protein BPC. It is chemically stable, resistant to degradation in gastric acid, and is reported to have a plasma half-life of less than 30 minutes with hepatic metabolism and renal clearance5. Unlike many peptide therapeutics, BPC-157 retains biological activity via oral, parenteral, and topical routes of administration10,18,7.

BPC-157 engages multiple, mechanistically distinct signaling pathways. A central mechanism involves the nitric oxide (NO) system: BPC-157 activates the Src-Caveolin-1-eNOS signaling cascade, phosphorylating both Src and eNOS while disrupting the inhibitory interaction between Caveolin-1 and eNOS, thereby facilitating endothelium-dependent NO generation and vasodilation4. Separately, it activates VEGFR2 through a ligand-independent mechanism involving receptor upregulation and endocytosis-dependent internalization, driving downstream Akt-eNOS signaling and promoting angiogenesis without increasing VEGF-A ligand levels3. In alkali burn wound healing, BPC-157 upregulates VEGF-A and activates ERK1/2 and its downstream transcription factors (c-Fos, c-Jun, Egr-1)7, suggesting context-dependent pathway engagement.

In tendon fibroblasts, BPC-157 upregulates growth hormone receptor (GHR) expression at both mRNA and protein levels and activates JAK2 upon growth hormone stimulation, sensitizing cells to GH-driven proliferation2. It also activates the FAK-paxillin signaling pathway, promoting cytoskeletal reorganization, cell migration, and cell survival under oxidative stress, without direct mitogenic activity15. In liver protection from radiation injury, BPC-157 upregulates the transcription factor KLF4, suppresses HIF-2α expression, reduces hepatocyte apoptosis, and decreases lipid accumulation — effects that are abolished by siRNA knockdown of KLF4, establishing it as a required mediator13.

A notable pharmacodynamic characteristic is that BPC-157 exerts modulatory rather than unidirectional effects on the NO system: it counteracts both NOS inhibitor-induced hypertension and NOS substrate-induced hypotension6, rescues both pro-hemorrhagic and pro-thrombocytopenic states induced by L-arginine and L-NAME respectively20, and in vitro generates NO through a mechanism resistant to inhibition by L-NAME even at 10-fold molar excess, suggesting activation of a non-canonical, NOS-independent NO-generating pathway6. This homeostatic NO modulation, combined with multi-pathway receptor engagement (VEGFR2, GHR, FAK, eNOS, KLF4), appears to underlie BPC-157's reported efficacy across diverse tissue types and injury models.

§04Evidence & efficacy

Evidence base
214Studies
44Human
73Animal

BPC-157 has demonstrated replicated preclinical efficacy across several biological domains. In tendon healing, it consistently improved biomechanical outcomes (load to failure, Young's modulus), functional recovery (Achilles Functional Index), and histological parameters across multiple independent animal studies9,12. It appears to accelerate early functional recovery in tendon-to-bone injury through dual anti-inflammatory and pro-angiogenic mechanisms, outperforming methylprednisolone on functional and vascular endpoints12.

In gastrointestinal protection, BPC-157 appears to reduce gastric and intestinal mucosal injury across multiple models including stress-induced ulcers, ethanol injury, cysteamine-induced lesions, NSAID toxicity, and antiplatelet drug-induced damage16,11,18. It was the only compound consistently effective across all three ulcer models in a comparative study that included H2 blockers, dopamine promoters, and gut peptides16. BPC-157 also appears to promote healing of colocutaneous fistulas via oral and systemic routes10.

Pro-angiogenic activity has been reported across multiple independent studies, with BPC-157 appearing to upregulate VEGFR2 expression and activate the VEGFR2-Akt-eNOS signaling pathway3, promote collateral vessel formation in venous ligation models8, and accelerate wound closure in alkali burn models through ERK1/2 and VEGF-A upregulation7.

In human studies, a retrospective case series of 12 patients with chronic knee pain reported that 7 of 12 patients experienced pain relief lasting more than 6 months following intraarticular BPC-157 injection5. A Phase 2 RCT evaluating BPC-157 for acute hamstring injury is currently underway with MRI-confirmed endpoints1.

§05Safety

Across the available preclinical literature, BPC-157 has consistently demonstrated a favorable tolerability profile. In acute and chronic dosing studies in rats and broiler chicks, no observable tissue or organ toxicity was reported at any dose tested, spanning a range from 10 pg/kg to 10 mcg/kg9,17. BPC-157 administered chronically (5 weeks daily) in broiler chicks produced no adverse histopathological findings17. In normotensive animals, BPC-157 had no effect on baseline blood pressure, suggesting hemodynamic neutrality under normal physiological conditions6. No adverse events were reported in NSAID toxicity18, fistula healing10, tendon repair9,12, radiation liver injury13, or vascular ligation models8.

A systematic review of preclinical orthopaedic literature confirmed no adverse effects across several organ systems in animal models, while noting that clinical safety data are currently absent5. The compound is metabolized hepatically with a half-life of less than 30 minutes and is renally cleared5. A registered Phase 1 safety and pharmacokinetics study in healthy human volunteers exists14, but no results have been published, meaning formal human tolerability data are still emerging. BPC-157 is listed as a prohibited substance by relevant anti-doping organizations for use in professional sport5.

No drug interactions have been formally characterized, though animal studies indicate BPC-157 modulates responses to anticoagulants (heparin, warfarin)20, NO-system agents (L-NAME, L-arginine)6,10,19, NSAIDs18, and corticosteroids10,12 — relationships that warrant clinical attention as human studies develop.

§06History

BPC-157 was isolated and characterized by Predrag Sikirić and colleagues at the University of Zagreb, Croatia, beginning in the early 1990s. The peptide was identified as a partial sequence of human gastric juice protein BPC and was initially studied for its gastroprotective properties. The earliest published characterization appeared in 1994, demonstrating protective efficacy across restraint stress, cysteamine, and ethanol-induced ulcer models — outperforming established reference compounds including H2 receptor antagonists and somatostatin16.

Through the late 1990s, the Zagreb group expanded research into the peptide's interactions with the nitric oxide system, demonstrating that BPC-157 could modulate NO-mediated blood pressure and tissue protection through mechanisms distinct from classical NOS substrates or inhibitors6,17. By the early 2000s, research had extended into musculoskeletal applications, with a landmark 2003 Journal of Orthopaedic Research study demonstrating accelerated Achilles tendon healing across biomechanical, functional, and histological endpoints9.

BPC-157 entered formal clinical development under the designation PL14736 for inflammatory bowel disease, with a Phase 1 safety and pharmacokinetics trial registered in 2015 by PharmaCotherapia d.o.o.14. Mechanistic research through the 2010s identified VEGFR2 upregulation3, FAK-paxillin pathway activation15, GHR sensitization2, and Src-Caveolin-1-eNOS signaling4 as key molecular mechanisms. In 2025, a systematic review in HSS Journal confirmed near-exclusive reliance on preclinical data5. A Phase 2 RCT in acute hamstring injury, sponsored by Hudson Biotech, was registered in 2026 — marking the first adequately powered randomized human trial of BPC-157 for a musculoskeletal indication1.

§07References